Eris Lifesciences Limited

NSEI:ERIS Voorraadrapport

Marktkapitalisatie: ₹183.4b

Eris Lifesciences Toekomstige groei

Future criteriumcontroles 4/6

Eris Lifesciences zal naar verwachting groeien in winst en omzet met respectievelijk 30.7% en 16.2% per jaar. De winst per aandeel zal naar verwachting groeien met 30.7% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 18.8% zijn.

Belangrijke informatie

30.7%

Groei van de winst

30.7%

Groei van de winst per aandeel

Pharmaceuticals winstgroei18.3%
Inkomstengroei16.2%
Toekomstig rendement op eigen vermogen18.8%
Dekking van analisten

Good

Laatst bijgewerkt01 Nov 2024

Recente toekomstige groei-updates

Recent updates

Eris Lifesciences Limited Just Missed EPS By 8.6%: Here's What Analysts Think Will Happen Next

Oct 30
Eris Lifesciences Limited Just Missed EPS By 8.6%: Here's What Analysts Think Will Happen Next

A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)

Oct 15
A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)

Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why

Sep 19
Eris Lifesciences Limited's (NSE:ERIS) CEO Compensation Looks Acceptable To Us And Here's Why

Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 27%

Sep 03
Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS) As Its Stock Soars 27%

Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Aug 05
Earnings Update: Eris Lifesciences Limited (NSE:ERIS) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

Aug 04
Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

Estimating The Intrinsic Value Of Eris Lifesciences Limited (NSE:ERIS)

Jul 13
Estimating The Intrinsic Value Of Eris Lifesciences Limited (NSE:ERIS)

Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

May 24
Eris Lifesciences Limited (NSE:ERIS) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price

May 10
Why We're Not Concerned About Eris Lifesciences Limited's (NSE:ERIS) Share Price

An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued

Mar 14
An Intrinsic Calculation For Eris Lifesciences Limited (NSE:ERIS) Suggests It's 25% Undervalued

Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report

Feb 15
Analyst Estimates: Here's What Brokers Think Of Eris Lifesciences Limited (NSE:ERIS) After Its Third-Quarter Report

Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)

Dec 28
Earnings Tell The Story For Eris Lifesciences Limited (NSE:ERIS)

Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

Dec 07
Eris Lifesciences (NSE:ERIS) Seems To Use Debt Quite Sensibly

Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Nov 11
Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Jul 20
Are Eris Lifesciences Limited (NSE:ERIS) Investors Paying Above The Intrinsic Value?

Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?

Nov 20
Does Eris Lifesciences (NSE:ERIS) Have A Healthy Balance Sheet?

These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely

Jun 20
These 4 Measures Indicate That Eris Lifesciences (NSE:ERIS) Is Using Debt Safely

A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)

Feb 24
A Look At The Fair Value Of Eris Lifesciences Limited (NSE:ERIS)

Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?

Dec 28
Is Now The Time To Put Eris Lifesciences (NSE:ERIS) On Your Watchlist?

Here's Why I Think Eris Lifesciences (NSE:ERIS) Might Deserve Your Attention Today

Sep 23
Here's Why I Think Eris Lifesciences (NSE:ERIS) Might Deserve Your Attention Today

If You Like EPS Growth Then Check Out Eris Lifesciences (NSE:ERIS) Before It's Too Late

May 26
If You Like EPS Growth Then Check Out Eris Lifesciences (NSE:ERIS) Before It's Too Late

Eris Lifesciences Limited (NSE:ERIS) Shares Could Be 34% Above Their Intrinsic Value Estimate

Apr 17
Eris Lifesciences Limited (NSE:ERIS) Shares Could Be 34% Above Their Intrinsic Value Estimate

Eris Lifesciences Limited's (NSE:ERIS) Stock Has Fared Decently: Is the Market Following Strong Financials?

Mar 12
Eris Lifesciences Limited's (NSE:ERIS) Stock Has Fared Decently: Is the Market Following Strong Financials?

Does Eris Lifesciences (NSE:ERIS) Deserve A Spot On Your Watchlist?

Feb 25
Does Eris Lifesciences (NSE:ERIS) Deserve A Spot On Your Watchlist?

Why Eris Lifesciences Limited (NSE:ERIS) Is A Dividend Rockstar

Feb 12
Why Eris Lifesciences Limited (NSE:ERIS) Is A Dividend Rockstar

Eris Lifesciences Limited (NSE:ERIS) Analysts Are Pretty Bullish On The Stock After Recent Results

Jan 30
Eris Lifesciences Limited (NSE:ERIS) Analysts Are Pretty Bullish On The Stock After Recent Results

Read This Before Buying Eris Lifesciences Limited (NSE:ERIS) Shares

Jan 17
Read This Before Buying Eris Lifesciences Limited (NSE:ERIS) Shares

Our View On Eris Lifesciences' (NSE:ERIS) CEO Pay

Dec 30
Our View On Eris Lifesciences' (NSE:ERIS) CEO Pay

Is Eris Lifesciences Limited's (NSE:ERIS) Recent Performance Tethered To Its Attractive Financial Prospects?

Dec 10
Is Eris Lifesciences Limited's (NSE:ERIS) Recent Performance Tethered To Its Attractive Financial Prospects?

Winst- en omzetgroeiprognoses

NSEI:ERIS - Toekomstschattingen van analisten en financiële gegevens uit het verleden (INR Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
3/31/202738,5027,1889,35511,1139
3/31/202634,0675,4538,4049,8759
3/31/202530,0613,807-11,0086,9319
9/30/202424,8533,4855,9317,068N/A
6/30/202422,4693,803N/AN/AN/A
3/31/202419,9133,9203,5684,860N/A
12/31/202318,4063,864N/AN/AN/A
9/30/202317,7503,856-3,3024,446N/A
6/30/202317,2983,824N/AN/AN/A
3/31/202316,6183,822-5,4972,917N/A
12/31/202215,6633,970N/AN/AN/A
9/30/202214,7663,9594192,844N/A
6/30/202213,7463,940N/AN/AN/A
3/31/202213,2624,0612,5723,783N/A
12/31/202112,9933,941N/AN/AN/A
9/30/202112,7633,8344,0584,428N/A
6/30/202112,4823,728N/AN/AN/A
3/31/202111,9263,5513,4963,754N/A
12/31/202011,6253,432N/AN/AN/A
9/30/202011,1923,1651,2112,724N/A
6/30/202010,7443,015N/AN/AN/A
3/31/202010,5822,9651,1992,712N/A
12/31/201910,2522,943N/AN/AN/A
9/30/201910,1193,1102,2192,599N/A
6/30/20199,9203,036N/AN/AN/A
3/31/20199,6722,9081,8502,230N/A
12/31/20189,8512,925N/AN/AN/A
9/30/20189,4422,870N/AN/AN/A
6/30/20189,2122,945N/AN/AN/A
3/31/20188,1962,941N/A2,346N/A
12/31/20178,0262,800N/AN/AN/A
9/30/20177,7812,735N/AN/AN/A
6/30/20177,2772,505N/AN/AN/A
3/31/20177,2052,468N/A2,002N/A
3/31/20165,9671,112N/A1,315N/A
3/31/20155,456892N/A901N/A
3/31/20145,088704N/A896N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei ERIS ( 30.7% per jaar) ligt boven de spaarquote ( 6.7% ).

Winst versus markt: De winst van ERIS ( 30.7% per jaar) zal naar verwachting sneller groeien dan de Indian markt ( 18.1% per jaar).

Hoge groeiwinsten: De winst van ERIS zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van ERIS ( 16.2% per jaar) zal naar verwachting sneller groeien dan de markt Indian ( 10.2% per jaar).

Hoge groei-inkomsten: De omzet van ERIS ( 16.2% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen ERIS zal naar verwachting over 3 jaar laag zijn ( 18.8 %).


Ontdek groeibedrijven